Drug developer Novavax Inc. completed enrolling 30,000 volunteers in a late-stage study of the company’s Covid-19 vaccine in the United States and Mexico.

Novavax announced a Memorandum of Understanding (MOU) with Gavi, the Vaccine Alliance, to provide 1.1 billion doses of the company’s Covid-19 vaccine candidate NVX-CoV2373 for the COVAX Facility.

Mexico surpassed India in confirmed Covid-19 deaths on Jan. 29, giving the Latin American country the third-highest toll worldwide, according to a Reuters tally of official data.

More than 1 million people have died from Covid-19 in North and South America, the Pan American Health Organization (PAHO) said.

Novavax Inc. started a large late-stage study of the company’s experimental Covid-19 vaccine in the United States after delaying the trial twice due to issues in scaling up the manufacturing process.

COVID-19 cases still surging in the Americas, the WHO warns BRASILIA (Reuters) – COVID-19 cases are still surging in the Americas, averaging 150,000 a day in last week, the World Health Organization’s regional office said on Wednesday. The United States continues to report record-breaking numbers, while parts of Canada and some states in Mexico, including […]

The Takeda Pharmaceutical Co.-led group that is developing a blood plasma treatment for Covid-19 started manufacturing while the late-stage trial to determine whether the hyperimmune globulin therapy works is ongoing, Chief Executive Christophe Weber said.

Johnson & Johnson aims to test the company’s experimental coronavirus vaccine in up to 60,000 volunteers in a late-stage trial scheduled to start in September, according to a U.S. government database of clinical trials.

Mexico aims to conduct late-stage clinical trials for Covid-19 vaccines in development by U.S. and Chinese companies, two of which might base some of their vaccine production in the country, the foreign ministry said.

Regeneron Pharmaceuticals – with the U.S. National Institute of Allergy and Infectious Diseases (NIAID) – is launching Phase III trials of REGN-COV2, the company’s two-antibody cocktail for the treatment and prevention of COVID-19.